Sansure Biotech Inc.

Symbol: 688289.SS

SHH

20.62

CNY

Market price today

  • 31.0215

    P/E Ratio

  • 0.0048

    PEG Ratio

  • 11.83B

    MRK Cap

  • 0.03%

    DIV Yield

Sansure Biotech Inc. (688289-SS) Financial Statements

On the chart you can see the default numbers in dynamics for Sansure Biotech Inc. (688289.SS). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Sansure Biotech Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

balance-sheet.row.cash-and-short-term-investments

04781.85663.84682.7
4192
165.5
127
39.9

balance-sheet.row.short-term-investments

0548.32451.22046.5
1601.2
66.3
0
0

balance-sheet.row.net-receivables

0732.81472.7894.1
606.7
195.6
171.1
134.1

balance-sheet.row.inventory

0376.6355.3369.5
276.7
64.7
55.9
40.9

balance-sheet.row.other-current-assets

058.433.620
7.2
11.5
5.1
103.6

balance-sheet.row.total-current-assets

05949.67525.45966.2
5082.7
437.2
359.1
318.4

balance-sheet.row.property-plant-equipment-net

01055.2785.3481
216.5
176.5
162.7
161.1

balance-sheet.row.goodwill

07.700
0
0
0
0

balance-sheet.row.intangible-assets

032884.445.6
31.2
11.5
11.2
10.7

balance-sheet.row.goodwill-and-intangible-assets

0335.684.445.6
31.2
11.5
11.2
10.7

balance-sheet.row.long-term-investments

0974.3-1793.8-1533.2
-1498.7
4.8
3.4
4

balance-sheet.row.tax-assets

073.869.625
17.2
11.5
11.9
15.8

balance-sheet.row.other-non-current-assets

065.62502.82105.8
1605.4
1
3.6
55.6

balance-sheet.row.total-non-current-assets

02504.61648.31124.1
371.7
205.3
192.9
247.2

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

08454.29173.87090.4
5454.4
642.5
552
565.6

balance-sheet.row.account-payables

0468.7791.4258.7
272.3
35.3
42.6
21.6

balance-sheet.row.short-term-debt

077.214.38.5
55
-6.6
0
0

balance-sheet.row.tax-payables

017.7216.4101.3
112.1
4.7
4
1.9

balance-sheet.row.long-term-debt-total

018.213.66.4
3.2
0
0
0

Deferred Revenue Non Current

032.530.525.7
19
11.4
10.6
10.1

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

0340.5712.92.4
3.3
38.1
102.6
99.3

balance-sheet.row.total-non-current-liabilities

077.789.345.1
20.3
11.6
10.6
65.7

balance-sheet.row.other-liabilities

0000
0
0
0
0

balance-sheet.row.capital-lease-obligations

018.213.66.4
3.2
0
0
0

balance-sheet.row.total-liab

0996.81661709
708.9
85
155.8
186.6

balance-sheet.row.preferred-stock

0000
0
0
0
0

balance-sheet.row.common-stock

0588.5588.5400
400
360
127.9
127.9

balance-sheet.row.retained-earnings

04882.75077.13820
2026.6
-28.2
-300.4
-307.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

0395.2377.4294
263.8
0
0
0

balance-sheet.row.other-total-stockholders-equity

01334.91457.71854.9
2054.9
225.7
568.8
558.3

balance-sheet.row.total-stockholders-equity

07201.37500.66368.9
4745.4
557.5
396.3
379

balance-sheet.row.total-liabilities-and-stockholders-equity

08454.29173.87090.4
5454.4
642.5
552
565.6

balance-sheet.row.minority-interest

0223.612.212.4
0
0
0
0

balance-sheet.row.total-equity

07424.97512.86381.3
4745.4
557.5
396.3
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-

Total Investments

01522.6657.4513.2
102.5
66.3
3.4
4

balance-sheet.row.total-debt

095.427.914.9
55
0
0
0

balance-sheet.row.net-debt

0-4138-3184.7-2621.3
-2535.8
-99.2
-127
-39.9

Cash Flow Statement

The financial landscape of Sansure Biotech Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017

cash-flows.row.net-income

01936.72242.52616.6
39.5
6.8
-10.7

cash-flows.row.depreciation-and-amortization

089.153.926.7
20.6
20.1
19.4

cash-flows.row.deferred-income-tax

0-40-8.1-4.6
0.7
0
0

cash-flows.row.stock-based-compensation

060.85.64.6
7.8
0
0

cash-flows.row.change-in-working-capital

0203.3-402.1-50.4
-49.7
-28.1
-90

cash-flows.row.account-receivables

0-496.5-304.1-419.4
-33.8
0
0

cash-flows.row.inventory

0-282.1-93-212.1
-8.8
-15.1
-0.3

cash-flows.row.account-payables

0496.53.1585.7
-7.8
0
0

cash-flows.row.other-working-capital

0485.4-8.1-4.6
0.7
-13
-89.7

cash-flows.row.other-non-cash-items

0308.9-14.849.4
3.5
11.3
19.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-558.8-372.9-108.7
-34.1
-32.9
-20.7

cash-flows.row.acquisitions-net

0-11.615.9115
0.4
0.6
0

cash-flows.row.purchases-of-investments

0-12140.6-7880-3725
-195
-100
-0.9

cash-flows.row.sales-maturities-of-investments

011591.17125.62111.3
130.9
100.7
0

cash-flows.row.other-investing-activites

0-46.9-0.9-108.7
3.2
109.1
-44.2

cash-flows.row.net-cash-used-for-investing-activites

0-1166.7-1112.2-1716
-94.6
77.5
-65.7

cash-flows.row.debt-repayment

0-17.2-55-55
0
0
-109.4

cash-flows.row.common-stock-issued

0274.62000
0
0
0

cash-flows.row.common-stock-repurchased

0-257.4-2000
0
0
0

cash-flows.row.dividends-paid

0-656.9-439.9-301.3
0
0
-5.6

cash-flows.row.other-financing-activites

0-259-193.71966.2
44.4
0
262.3

cash-flows.row.net-cash-used-provided-by-financing-activities

0-915.9-688.61609.9
44.4
0
147.3

cash-flows.row.effect-of-forex-changes-on-cash

0-10-34.3-44.6
0
-0.1
-0.1

cash-flows.row.net-change-in-cash

0466.2422491.6
-27.8
87.5
20

cash-flows.row.cash-at-end-of-period

03099.12632.82590.8
99.2
127
39.5

cash-flows.row.cash-at-beginning-of-period

02632.82590.899.2
127
39.5
19.5

cash-flows.row.operating-cash-flow

02558.91877.12642.3
22.4
10.1
-61.4

cash-flows.row.capital-expenditure

0-558.8-372.9-108.7
-34.1
-32.9
-20.7

cash-flows.row.free-cash-flow

02000.11504.22533.6
-11.7
-22.8
-82.1

Income Statement Row

Sansure Biotech Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 688289.SS is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

income-statement-row.row.total-revenue

01002.56450.44514.5
4763
365.4
303.4
224.6

income-statement-row.row.cost-of-revenue

0381.82655.41279
970
127.3
126
112.7

income-statement-row.row.gross-profit

0620.737953235.5
3793
238.1
177.4
111.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

010.695.544.5
39.6
14.7
-1
30.4

income-statement-row.row.operating-expenses

0638.71262.2666.9
680.9
188.7
163.7
127.1

income-statement-row.row.cost-and-expenses

01020.53917.51945.9
1650.8
316
289.8
239.8

income-statement-row.row.interest-income

054.748.432.5
16.7
0.2
5.1
6.1

income-statement-row.row.interest-expense

02.42.10.8
0.5
0.5
3.2
16.4

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0450.7-23.9-5.6
-15.9
-2.1
-3
17.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

010.695.544.5
39.6
14.7
-1
30.4

income-statement-row.row.total-operating-expenses

0450.7-23.9-5.6
-15.9
-2.1
-3
17.9

income-statement-row.row.interest-expense

02.42.10.8
0.5
0.5
3.2
16.4

income-statement-row.row.depreciation-and-amortization

0136.8290.8-20.7
25.8
21.4
20.1
19.4

income-statement-row.row.ebitda-caps

0---
-
-
-
-

income-statement-row.row.operating-income

0-182339.82621.8
3086
47.5
11.7
-27.7

income-statement-row.row.income-before-tax

0432.62315.92616.2
3070.2
45.5
10.7
2.6

income-statement-row.row.income-tax-expense

062.3379.2373.7
453.6
6
3.9
13.3

income-statement-row.row.net-income

0363.71936.82242.7
2616.6
39.5
6.8
-10.7

Frequently Asked Question

What is Sansure Biotech Inc. (688289.SS) total assets?

Sansure Biotech Inc. (688289.SS) total assets is 8454204974.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.729.

What is company free cash flow?

The free cash flow is -0.496.

What is enterprise net profit margin?

The net profit margin is 0.321.

What is firm total revenue?

The total revenue is 0.334.

What is Sansure Biotech Inc. (688289.SS) net profit (net income)?

The net profit (net income) is 363721131.000.

What is firm total debt?

The total debt is 95444005.000.

What is operating expences number?

The operating expences are 638676546.000.

What is company cash figure?

Enretprise cash is 0.000.